Bioquell Share Discussion Threads

[fatfin] 07/1/2008 20:11

These were tipped in moneyweek last friday.

Still in oilexco bounty?. I sold out and kept my venture prod. Bad call.

Hopefully these will drop back a bit after this then I may come in for some.

A mix of copper and lino in hospitals is also a very good killer of Mrs A and one hospital has moved over to all Cu fingerplates, skirtings etc.with lino floors. It will be interesting to see if it is ever mentioned again. Meanwhile this looks a winner.

Fatfin

[bountyhunter] 07/1/2008 19:51

nice rise today for BQE on a generally dour day for the markets

[parvez] 21/12/2007 09:07

here we go again having consolidated - wonder if these will be tipped in the new year?

[bountyhunter] 11/12/2007 16:52

yes looking good again today - no idea why the sudden movement though!

[basketbob] 11/12/2007 16:03

Up nearly 12% today on little volume, mostly sells showing. What gives?

[parvez] 07/12/2007 15:39

here we go...

[parvez] 07/12/2007 08:05

fidra,
I'd agree with you. Just bought some. Winterfllods biding for 25k and only offering 100 shares!!

[wes1] 02/11/2007 14:47

Attaining Category One status with NHS is a key to the door of hospitals worldwide.

This article is new on the net - note the final paragraph

It's not only hospitals, in the US there has been a lot of publicity about community acquired MRSA after outbreaks at Connecticut high schools and the death of a student in Virginia.

Prisons are also reporting cases of caMRSA

[bountyhunter] 02/11/2007 13:48

I agree, I'm hanging on here for those reasons.

[fidra] 02/11/2007 08:30

I think there is more mileage in this yet.Only capped at £100m.Good product.The health minister saying she is having a big push on dirty hospitals and mrsa.

I would not bet the house ,but good potential.Even as an add on for someone else.

[scotswhaehae] 30/10/2007 10:50

Fantstic recent performance and no doubt still cheap on a 3 year view...but probably sensible to take trading profits...

What a great ride!

[wjccghcc] 29/10/2007 22:10

Only problem is they kind of misjudged how quick it would be to get approval and it still doesn't seem imminent given they haven't even submitted the data yet.

TRAC seems a bit pedestrian and while the NHS cat 1 status is good news, I'm not sure it will lead to their tech being employed much more than it was going to be, particularly given that most in the industry know how effective it is anyway.

The defence side however is a jewel, at least for the next few years.

But, on latest upgraded forecasts, they're now on a PE of 32 for this year dropping to 29.5 next year which for 8% EPS growth is a bit rich for me, particularly if you compare them with the likes of Celsis on a PE of 13.5 dropping to 11.5 next year, so I've taken profits.

[wes1] 29/10/2007 17:13

Bioquell have been developing their wound healing technology for over 5 years. Just a question now of completing clinical trials and gathering the data for the Regulatory authorities here and in US.

chronic wounds such as leg ulcers, foot ulcers, pressure sores and surgical wounds affect up to 4.5 million Americans at a cost of more than $9.5 billion annually.

Leg ulcers are the most common of the chronic wounds with an estimated
occurrence in approximately 1% of the world's population, representing some 2.5 million people in the United States.

Leg ulcers are thought to occur in approximately 0.5 to 1.0% of the US population, rising to 5% in the elderly. In the UK, it has been estimated that
between 80,000 and 100,000 people suffer with a leg ulcer at any one time.

Venous leg ulcers alone account for the loss of 2 million US work days per year. In the UK, the financial cost of venous leg ulcers has been estimated at between £294 and £650 million per year

[cockneyrebel] 29/10/2007 16:35

Well BQE has got very excited by its MRSA treatment but have you looked at IP Group IPO ?

They have a 56% stake in Photopharmica who have developed an MRSA treatment that has just passed Phase II trials - and since then directors have been buying heavily, just last week, 2 months before year end. What's more IPO did over 7p eps in H1 alone so they look rather cheap imo.


I reckon the market will wake up to this one soon too.

"
IP Group plc


IP GROUP SPIN-OUT COMPANY, PHOTOPHARMICA, ANNOUNCES SUCCESSFUL PHASE II DATA

IP Group plc (LSE: IPO) ("IP Group"), the intellectual property commercialisation company, is delighted to note that Photopharmica Holdings Limited ("Photopharmica" or "the Company"), a University of Leeds spin-out company in which, as at the date hereof, IP Group has a 51.54% stake, has announced the successful completion of the first ever Phase II placebo-controlled clinical trial using topical photodynamic therapy (PDT) for the treatment of microbial disease in wounds.

The trial employed Photopharmica's proprietary drug, PPA 904, a member of the phenothiazinium family of photosensitisers. Photodynamic therapy with PPA 904 involves two stages: 1) the topical administration of PPA 904 to a site of infection where the drug is absorbed by resident bacteria; 2) the application of visible light of a pre-defined wavelength which triggers PPA 904 to release highly potent 'singlet' oxygen, thereby killing those bacteria that have taken up the drug.

The Phase IIa randomised, blinded, placebo-controlled study showed that a single PDT treatment achieved a statistically significant reduction in the bacterial load of chronic leg ulcers and diabetic foot ulcers compared with placebo. Further analysis showed that several types of bacterial species were killed in these treatments including MRSA.

In addition, there was evidence of a treatment effect on ulcer healing. For the leg ulcer group, 4 of 8 patients on active drug (50%) achieved complete healing within 3 months, whereas only 1 of 8 patients (12.5%) achieved complete healing in the placebo group.

The treatment was found to be safe and well-tolerated by patients. No treatment-related adverse events were reported.

Photopharmica plans to carry out further trials of PPA 904 in bacterially colonised chronic ulcers commencing in 2008. The Company regards the success of this first Phase II trial as a proof of principle which could lead to the application of its antimicrobial technology to a range of infective conditions involving skin and wounds.

The Company, which was established in 2001 to develop novel photosensitisers as products for medical use, has opened up new applications of topical photodynamic therapy and produced photosensitisers that have improved properties compared with those previously available. Photopharmica's first clinical trial was conducted in 2004.

Alan Aubrey, Chief Executive of IP Group, said: "We are delighted that Photopharmica has received successful phase II data. Photopharmica is the first company in the IP Group portfolio to have reached this significant milestone and, as such, demonstrates the continued development, depth and breadth of our life sciences portfolio."

Professor Stanley B Brown, Chief Scientific Officer of Photopharmica and Director, Centre for Photobiology and Photodynamic Therapy at the University of Leeds, said: "Our novel antimicrobial photodynamic therapy has been in laboratory development for several years but, for the first time, we now have convincing proof from a randomised, controlled clinical trial, that it works in patients and also evidence that it kills antibiotic resistant 'superbugs' like MRSA. The data are especially promising in showing evidence that wound healing may be accelerated in patients with long-standing, chronic leg ulcers. These are exciting results which we hope will lead to this novel therapy becoming available for the benefit of patients with a wide range of conditions."

[jonno1] 29/10/2007 11:34

just had a very nice plug from Patrick Evershed from New Star on Bloomberg

[basketbob] 29/10/2007 08:39

I see this going places fast. Hospital infections are a very emotive subject, and IMO a good bit of cash is going to be thrown at this in the short term.

[bountyhunter] 29/10/2007 07:02

Interesting, Bioquell seem to have quite a few websites including sites in French, Italian, and German - I've not seen the Irish one before. Just been reading about the 'Bioquell Z' which looks like a strong candidate for Dr. Who! ;)



"The BIOQUELL Z is a new, unique hydrogen peroxide vapour (HPV) generator designed to give rapid, repeatable and reliable eradication of bio-burden within any zone, room or suite."

[bountyhunter] 27/10/2007 18:06

glad I got back in here now - @173 around a month ago - just wish I'd bought more!

[borchardt] 27/10/2007 17:38

Also positive comments in todays Mail - looks good for Monday

[darkdogs] 27/10/2007 13:11

Royal devon And exeter been in the news today with regards c dif. Looks like BQE did a good job

[wes1] 27/10/2007 07:47

Article in The Times today with a "Buy" recommendation -

For three years Bioquell, a small British technology company, has managed to secure orders from overseas hospitals for its hospital superbug "zapper" but been frustrated by the unwillingness of NHS hospitals to use its services.

Yesterday, however, there was a step change for Bioquell. The Department of Health's Rapid Review Panel has upgraded Bioquell's kit – a portable device that sprays hydrogen peroxide vapour to decontaminate a room – to its Category One status. It means that the Government is pressing hospital trusts to make consideration of Bioqell's kit as a priority in their fight against a new form of clostridium difficile, the spore-forming superbug bacteria.

Three years ago Bioquell shares peaked at over 185p on hopes for an early NHS take-up of its kit. They fell as low as 97p last year. Yesterday they raced up 20p to a new high of 217p as investors rekindled their hopes for NHS business.

The company moved into cash generation towards the end of the last calendar year. It made a pretax profit of £500,000 on sales up 47 per cent to £25.2 million. Bioquell has since won a large deal with the US Army to decontaminate equipment exposed to biological warfare. NHS hospitals may not start spending until the new tax year, but fighting superbugs on the home front is bigger long-term business. Buy.

Edit - here is the link

[darkdogs] 26/10/2007 15:46

should be good for monday if the press picks up on this. hardly any buying today

[money multipier] 26/10/2007 14:51

Very nice news and the share price still climbing. Will we in future see levels of nhs business to rivel that in us hospitals?

[wes1] 26/10/2007 09:52

Categary One status -

"Superbug" (including C.diff) eradication technology for NHS hospitals

Upgrade of BIOQUELL's unique hydrogen peroxide vapour decontamination technology by the Department of Health's

Rapid Review Panel to Category One status

First "superbug" technology to be upgraded to Category One status


BIOQUELL PLC ("BIOQUELL") (LSE: BQE), the UK leader in specialist
decontamination technology and testing/compliance services, announces that its
"superbug" eradication technology has been upgraded by the Department of
Health's Rapid Review Panel ("RRP") to Category One status.

Background

* The RRP was set up by the Government in 2004 to facilitate the rapid
review by an independent panel of leading UK infection control experts of
the products / technologies which could be used to combat hospital acquired
infections - or "superbugs" - in NHS hospitals.

* BIOQUELL's hydrogen peroxide vapour ("HPV") decontamination technology was
one of the first technologies to be reviewed by the RRP. On 1 December,
2004, following a review of the scientific data available at the time, the
RRP awarded BIOQUELL's technology Category Two status, which meant that
"basic research and development has been completed and the product may have
potential value; in use evaluations / trials are now needed in an NHS
clinical setting"

Promotion to RRP Category One status

* Earlier this year BIOQUELL submitted extensive scientific data to the RRP
relating to its research activities and the deployment of its unique HPV
decontamination technology against "superbugs" in hospitals in the UK, US
and continental Europe.

* Having now completed its assessment, the RRP has upgraded BIOQUELL's HPV
technology to Category One status, which means that: "Basic research and
development, validation and recent in use evaluations have shown benefits
that should be available to NHS bodies to include as appropriate in their
cleaning, hygiene or infection control protocols."

* To date the RRP has reviewed 42 products or technologies to combat
"superbugs" in the 'Cleaning, Disinfection and Decontamination' category and
has awarded Category One status to only two - one being BIOQUELL.

* BIOQUELL's technology is the first product to be promoted to a new
category by the RRP - which is indicative of the quality and volume of
scientific efficacy data generated by BIOQUELL to support the use of its
technology to eradicate "superbugs" in hospitals.

* Further information on the promotion of BIOQUELL's technology to Category
One status is available on the Health Protection Agency's website at:

BIOQUELL's technology against Clostridium difficile

* A significant proportion of the scientific data submitted by BIOQUELL to
the RRP relate to the eradication of Clostridium difficile ("C.diff") from
sensitive electronic medical devices as well as rooms and wards in
hospitals. For example, BIOQUELL has had a team permanently based at a
leading US hospital for more than two years carrying out proactive
decontaminations against C.diff. - and research from this hospital suggested
that the use of BIOQUELL's technology directly contributed to a
statistically significant 53% reduction in C.difficile associated disease.

NHS / Department of Health "Clean, Safe Care" best practise website

* Abstracts of BIOQUELL's technology have recently been uploaded to an NHS /
Department of Health website highlighting case studies relating to best
practise involving the eradication or management of hospital acquired
infection. (See )

* The best practise website includes a description of the use of BIOQUELL's
technology to eradicate C.diff at Maidstone and Tunbridge Wells NHS Trust
following a C.diff outbreak (which has been the subject of an independent
report which was recently made public) (See )

Commenting on the promotion by the Rapid Review Panel of BIOQUELL's unique
"superbug" eradication technology to Category One status, Nick Adams, Chief
Executive of BIOQUELL PLC said:

"Clostridium difficile, MRSA and other "superbugs" remain a real, increasing and
sensitive problem for hospitals in the NHS and around the world, as was
underscored by the Prime Minister's announcement of a deep-clean for every NHS
hospital last month. Further, there have been a number of recent reports
highlighting the major clinical issues caused by C.diff in hospitals. Despite
the sensitivity of these problems, we are pleased that BIOQUELL is being asked
to help more and more NHS hospitals combat Clostridium difficile.

We are also delighted that the top UK experts on the Rapid Review Panel have
concluded that the use of BIOQUELL's unique decontamination technology to combat
"superbugs" is now supported by robust scientific data - and it has now been
awarded Category One status. We are also pleased to be the first technology to
be upgraded to Category One status by the Rapid Review Panel."